+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.

Age: 55Years - 90YearsAll GendersPhase 3
157 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining KarXT and KarX-EC as a treatment for psychosis associated with Alzheimers disease. This Phase 3 randomized, double-blind, placebo-controlled trial aims to address psychotic symptoms such as hallucinations and delusions in patients aged 55 to 90 diagnosed with Alzheimers disease according to recent criteria. The study is sponsored by Bristol-Myers Squibb and uses a parallel group design to compare the investigational drug combination against placebo. Participants will be randomly assigned to receive either the combination of KarXT plus KarX-EC or a matching placebo, with specified doses given on set days. The treatment period lasts approximately 14 weeks, during which safety and efficacy are closely monitored. The trial assesses changes from baseline in neuropsychiatric symptoms and other clinical measures using standardized scales and questionnaires. During the study, participants will undergo various assessments including clinical evaluations, laboratory tests, brain imaging review, and symptom rating scales such as the Neuropsychiatric Inventory-Clinician and Clinical Global Impressions-Severity. Researchers will also monitor adverse events and other health indicators up to about week 14. The total participation duration spans from screening through treatment completion and safety follow-up to evaluate the overall impact and safety profile of the treatments.

Age: 55Years - 90YearsAll GendersPhase 3
22 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
R

Actively Recruiting

Researchers are evaluating the use of intravenous hyperoncotic albumin compared to normal saline boluses in critically ill patients suffering from Acute Kidney Injury requiring renal replacement therapy AKI-RRT. This trial aims to determine whether albumin administration during renal replacement therapy sessions increases organ support-free days and renal replacement therapy-free days within 28 days after randomization. The study addresses the challenge that renal replacement therapy, while life-saving, may cause complications like hypotension and organ ischemia in these patients. Participants will be randomly assigned to receive either 20-25% albumin fluid or normal saline boluses during their renal replacement therapy sessions in the intensive care unit. Each treatment involves two 100 mL boluses one at the start and one halfway through each session. The renal replacement therapies include continuous renal replacement therapy CRRT, prolonged intermittent renal replacement therapy PIRRT, or intermittent hemodialysis IHD. Treatments will continue for up to 14 days in the ICU, with dosing schedules tailored to the type of renal replacement therapy. During the study, participants will be closely monitored for organ support-free days, renal replacement therapy-free days, and other health outcomes through 28 days, with extended follow-up for mortality and kidney function up to 365 days. Researchers will collect data on fluid balance, hypotension episodes during therapy, organ function scores, healthcare costs, and quality of life measures. The trial involves multiple intensive care units and includes comprehensive assessments to evaluate the impact and safety of albumin use in this critical condition.

Age: 18Years +All GendersPhase 4
16 locations
E

Actively Recruiting

Healthy Volunteer

Mood disorders, including depression and bipolar disorder, affect over 350 million people worldwide. Matching the right treatment to each individual is challenging and can lead to prolonged illness and reduced quality of life. This research aims to advance the search for biomarkersclinical tests, blood tests, or imagingthat can help diagnose and treat mood disorders by creating a large, standardized study platform called ENABLE. The ENABLE platform provides standardized methods to collect detailed clinical and neurobiological data from individuals aged 16 and older with mood disorder symptoms. Participants complete clinical assessments and may opt for additional tests such as blood samples, MRI and EEG scans, cognitive tasks, and wearing an activity monitor for two weeks. The platform also serves as a recruitment pool for future biomarker-based clinical trials and offers open-source data for research purposes. Participants will undergo tiered assessments, with tier 1 including required clinical interviews and questionnaires, and tier 2 offering optional neuroimaging, blood collection, cognitive testing, and actigraphy. Researchers will measure participation rates and collect data to support biomarker discovery. The study involves ongoing data collection and follow-up until March 2029, providing a resource for future clinical trials and scientific analyses.

Age: 16Years +All Genders
9 locations
T

Actively Recruiting

This trial studies whether cannabidiol CBD capsules can help manage agitation in patients with Alzheimers disease AD. It is a randomized, double-blind, placebo-controlled crossover study assessing the safety and effectiveness of CBD, while also exploring new biomarkers related to agitation severity and treatment response. Agitation is common in AD and linked to health problems and caregiver burden current treatments have limitations and safety concerns. Participants will receive either CBD or placebo capsules during two treatment phases, each lasting 8 weeks, separated by a 2-week placebo washout period. The CBD dose is gradually increased up to a maximum of 800 mg per day. The study involves 12 visits approximately every 2 weeks and 8 weekly telephone visits throughout the 19-week treatment period, followed by 4 weeks of observation after treatment ends. During the study, participants will undergo assessments of agitation using the Cohen-Mansfield Agitation Inventory and other evaluations including neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, weight, pain, and overall global change. Researchers will monitor these outcomes from baseline through 22 weeks to understand CBDs impact and safety in managing agitation in AD patients.

Age: 55Years +All GendersPhase 2
5 locations
P

Actively Recruiting

Researchers are evaluating whether nabilone, a synthetic cannabinoid approved for chemotherapy-related nausea, is an effective treatment for agitation in patients with Alzheimers disease AD. Agitation is common in AD and can worsen quality of life, increase caregiver burden, and speed institutionalization. Current treatments have limited effectiveness and notable risks, so this study aims to explore nabilones potential benefits for agitation and other symptoms in AD. Participants will be randomly assigned to receive either nabilone or placebo capsules for 8 weeks. Those in the nabilone group will have their dose gradually increased up to a maximum of 2 mg per day. After the treatment phase, all participants will be followed for an additional 8 weeks to monitor ongoing effects. The study uses a quadruple-blind design to compare outcomes between the two groups. During the study, participants will undergo assessments of agitation using the Cohen-Mansfield Agitation Inventory, as well as evaluations of behavior, cognition, weight, nutritional status, pain, and global clinical change. Caregivers will also participate in study visits and assessments. The research team will closely monitor these factors from the start through 8 weeks after treatment ends to understand the effects and safety of nabilone in this population.

Age: 55Years +All GendersPhase 3
6 locations
L

Actively Recruiting

Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.

Age: 55Years - 90YearsAll GendersPhase 3
432 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a predictive biomarker algorithm designed to guide medication treatment for patients experiencing a major depressive episode within major depressive disorder MDD. This multi-site randomized study builds on data from a previous study and aims to integrate clinical, imaging, EEG, and molecular information to better predict treatment outcomes for participants. The study involves both patients with MDD and healthy controls to collect comprehensive data for analysis. Participants with MDD will be randomly assigned to one of two groups a Personalized Assignment group, where medication selection is guided by the biomarker algorithm, and a Random Assignment group, where medication is assigned without algorithm guidance. All patients receive open-label escitalopram 10-20 mg per day for 12 weeks. Depending on group and response prediction, participants may also receive blinded brexpiprazole 0.5-2 mg per day or placebo for the first 8 weeks, followed by an open-label phase of 4 weeks with medication adjustments based on treatment response. Over the 12-week period, participants attend seven study visits involving clinical assessments, cognitive tests, sample collections blood, urine, stool, neuroimaging MRI and EEG, and speech samples. The main outcome measure is the change in Montgomery Asberg Depression Rating Scale MADRS scores over the first 8 weeks. Researchers will use all collected data to identify features that best predict treatment response. Safety and clinical response will be monitored throughout the study with ongoing evaluations.

Age: 18Years - 65YearsAll GendersPhase 4
10 locations

1-10 of 16

1